Finding new drugs to target SATB2 in pancreatic cancer
Discovery of SATB2 Inhibitors for Pancreatic Cancer
This study is looking at new safe medications that can block a protein called SATB2, which is found in high amounts in pancreatic cancer cells, to see if this can help slow down tumor growth and make treatments more effective for patients.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Glax, LLC NIH-funded |
| Lab location | 1 site (Wilmington, United States) |
| Project ID | NIH-11026366 on NIH RePORTER |
What this research studies
This research focuses on developing new non-toxic drugs that inhibit SATB2, a protein that is highly expressed in pancreatic cancer cells and cancer stem cells. The study aims to understand how SATB2 contributes to the growth and survival of these cancer cells, which are often resistant to current treatments. By targeting SATB2, the researchers hope to reduce tumor growth and improve patient outcomes. The approach involves investigating the role of SATB2 in gene expression and cancer cell behavior.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic cancer, particularly those who have not responded well to existing therapies.
Not a fit: Patients with early-stage pancreatic cancer who are responding well to current treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic treatments for pancreatic cancer patients.
How similar studies have performed: While targeting SATB2 is a novel approach, similar strategies targeting cancer stem cells have shown promise in other types of cancer.
Where this research is happening
Wilmington, United States
- Glax, LLC — Wilmington, United States (Active)
Researchers
- Principal investigator: Srivastava, Rakesh K. — Glax, LLC
- Study coordinator: Srivastava, Rakesh K.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.